Optimized dendritic cell-based immunotherapy for melanoma: The TriMix-formula

Cancer Immunology, Immunotherapy

Volumn 63, Issue 9, 2014, Pages 959-967

  Van Lint, Sandra ^a   Wilgenhof, Sofie ^a,b   Heirman, Carlo ^a   Corthals, Jurgen ^a   Breckpot, Karine ^a   Bonehill, Aude ^a   Neyns, Bart ^b   Thielemans, Kris ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

19th Danish Cancer Society Symposium 2013; Cancer; Dendritic cell; Immunotherapy; mRNA

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN GP 100; MAGE C2 PROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; MRNA VACCINE; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL STUDY; DENDRITIC CELL; ELECTROPORATION; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; PROCEDURES;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA;

EID: 84906939134     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1558-3     Document Type: Review

References (56)

1. Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7:543-555 (Pubitemid 46987783)
2. Melief CJM (2008) Cancer immunotherapy by dendritic cells. Immunity 29:372-383
3. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-277
4. Vacchelli E, Vitale I, Eggermont A et al (2013) Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2:e25771
5. Galluzzi L, Senovilla L, Vacchelli E et al (2012) Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 1:1111-1134
6. Jonuleit H, Giesecke-Tuettenberg A, Tüting T et al (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243-251 (Pubitemid 32574281)
7. De Vries IJM, Lesterhuis WJ, Scharenborg NM et al (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091-5100 (Pubitemid 37413557)
8. Steinman RM, Nussenzweig MC (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 99:351-358 (Pubitemid 34060366)
9. Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23:445-449 (Pubitemid 35015188)
10. Cools N, Van Tendeloo VFI, Smits ELJM et al (2008) Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells. J Cell Mol Med 12:690-700 (Pubitemid 351555146)
11. Enk AH (2005) Dendritic cells in tolerance induction. Immunol Lett 99:8-11
12. Jonuleit H, Kühn U, Müller G et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142 (Pubitemid 28018007)
13. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al (2004) Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934-5937 (Pubitemid 39129387)
14. Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-883 (Pubitemid 350002889)
15. Turner JG, Rakhmilevich AL, Burdelya L et al (2001) Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 166:89-94 (Pubitemid 32038420)
16. Nair S, McLaughlin C, Weizer A et al (2003) Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171:6275-6282 (Pubitemid 37467251)
17. Adema GJ, de Vries IJM, Punt CJA, Figdor CG (2005) Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 17:170-174 (Pubitemid 40343104)
18. Calderhead DM, DeBenedette MA, Ketteringham H et al (2008) Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother 31:731-741
19. DeBenedette MA, Calderhead DM, Tcherepanova IY et al (2011) Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother 34:45-57
20. Bonehill A, Tuyaerts S, Van Nuffel AMT et al (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170-1180 (Pubitemid 351737084)
21. Kikuchi T, Moore MA, Crystal RG (2000) Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96:91-99 (Pubitemid 30456456)
22. Cisco RM, Abdel-Wahab Z, Dannull J et al (2004) Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol 172:7162-7168 (Pubitemid 38669160)
23. Borst J, Hendriks J, Xiao Y (2005) CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17:275-281 (Pubitemid 40692662)
24. Van Lint S, Van Nuffel AM, Wilgenhof S, et al. (2013) Priming of cytotoxic T lymphocyte responses by dendritic cells: induction of potent anti-tumor immune responses. Cytotoxic T lymphocytes Mech Dev Dis, Horizons i. Nova Science Publishers, p volume 51
25. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1:311-316
26. Bonehill A, Van Nuffel AMT, Corthals J et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366-3375
27. Wilgenhof S, Van Nuffel AMT, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448-456
28. Pen JJ, De Keersmaecker B, Maenhout SK et al (2013) Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol 191:1976-1983
29. Fong L, Brockstedt D, Benike C et al (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166:4254-4259 (Pubitemid 32224961)
30. Mullins DW, Sheasley SL, Ream RM et al (2003) Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198:1023-1034 (Pubitemid 37248618)
31. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
32. Wilgenhof S, Van Nuffel AMT, Benteyn D et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686-2693
33. Van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied. J Exp Med 190:355-366 (Pubitemid 29374833)
34. Neyns B, Wilgenhof S, Van Nuffel AMT et al (2011) A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). ASCO Meet Abstr 29:2519
35. Van Lint S, Heirman C, Thielemans K, Breckpot K (2013) mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9(2):265-274
36. Van Lint S, Goyvaerts C, Maenhout S et al (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72:1661-1671
37. Kuhn AN, Diken M, Kreiter S et al (2011) Determinants of intracellular RNA pharmacokinetics: implications for RNA-based immunotherapeutics. RNA Biol 8:35-43
38. Probst J, Brechtel S, Scheel B et al (2006) Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther 4:4
39. Diken M, Kreiter S, Selmi A et al (2011) Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 18:702-708
40. Kreiter S, Diken M, Selmi A et al (2011) Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23:399-406
41. Pascolo S (2006) Vaccination with messenger RNA. Methods Mol Med 127:23-40
42. Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285-1294
43. Bringmann A, Held SAE, Heine A, Brossart P (2010) RNA vaccines in cancer treatment. J Biomed Biotechnol 2010:623687
44. Kuhn AN, Beißert T, Simon P et al (2012) mRNA as a versatile tool for exogenous protein expression. Curr Gene Ther 12:347-361
45. Ulmer JB, Mason PW, Geall A, Mandl CW (2012) RNA-based vaccines. Vaccine 30:4414-4418
46. Kreiter S, Castle JC, Türeci O, Sahin U (2012) Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1:768-769
47. Castle JC, Kreiter S, Diekmann J et al (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72:1081-1091
48. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
49. Britten CM, Singh-Jasuja H, Flamion B et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31:880-882
50. Le Dieu R, Taussig DC, Ramsay AG et al (2009) Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 114:3909-3916
51. Ramsay AG, Clear AJ, Kelly G et al (2009) Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114:4713-4720
52. Ramsay AG, Johnson AJ, Lee AM et al (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437 (Pubitemid 351949771)
53. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
54. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454
55. Brahmer JR, Tykodi S, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465
56. Pruitt SK, Boczkowski D, de Rosa N et al (2011) Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 41:3553-3563